Idexx Laboratories (IDXX) Cash & Equivalents (2009 - 2026)

Idexx Laboratories (IDXX) has reported Cash & Equivalents for 18 consecutive years, with $200.5 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash & Equivalents rose 22.3% year-over-year to $200.5 million; the TTM figure through Mar 2026 stood at $200.5 million (up 22.3% YoY), while the FY2025 annual figure was $180.1 million, down 37.53% from the prior year.
• Cash & Equivalents came in at $200.5 million for Q1 2026 at Idexx Laboratories, up from $180.1 million in the prior quarter.
• The five-year high for Cash & Equivalents was $453.9 million in Q4 2023, with the low at $99.2 million in Q3 2022.
• Average Cash & Equivalents over 5 years is $227.9 million, with a median of $200.5 million recorded in 2026.
• Across the five-year window, Cash & Equivalents soared 303.33% in 2023 and tumbled 59.01% in 2025, its largest moves.
• Year by year, Cash & Equivalents stood at $112.5 million in 2022, then surged by 303.33% to $453.9 million in 2023, then plunged by 36.5% to $288.3 million in 2024, then slumped by 37.53% to $180.1 million in 2025, then advanced by 11.36% to $200.5 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $200.5 million, $180.1 million, and $208.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.